Publications
- The translocation t(2;11)(p21;q23) without MLL gene rearrangement-a possible marker of good prognosis in myelodysplastic syndrome patients2014 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Notes to the pathophysiology of myelodysplastic syndrome, demethylation therapy and the role of cytokine-induced differentiation2013 | First Faculty of Medicine
- Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II2013 | First Faculty of Medicine
- Current recommendations in chelation therapy2013 | First Faculty of Medicine
- Deferasirox in patients with myelodysplastic syndrome and iron overload - Results of the EPIC study - Commenting on the study2013 | First Faculty of Medicine
- A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes2013 | Publication without faculty affiliation
- Changes associated with lenalidomide treatment in the gene expression profiles of patients with Del(5q)2012 | First Faculty of Medicine
- Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports2012 | First Faculty of Medicine
- 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity2012 | First Faculty of Medicine
- Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome2011 | First Faculty of Medicine
Loading network view...